The FDA has granted St. Jude Medical approval to market the EnSite Velocity™ Cardiac Mapping System. This new package lets cardiologists create comprehensive electrophysiological maps of the heart through a simultaneous use of multiple catheters and electrodes. The company claims that the EnSite Velocity™ is specifically designed to decrease fluoroscope exposure by patients and clinicians:
[T]he system offers simple set-up and connections, an intuitive software interface and includes two key new capabilities: the OneMap(TM) tool and RealReview(TM) function. The OneMap tool enables physicians to create a detailed cardiac model and electrical map together using multiple catheters and electrodes, allowing physicians to collect and display more relevant patient information in a shorter amount of time. The RealReview function provides real-time, side-by-side views of the live procedure and previously recorded portions of the procedure. This feature gives physicians a quick and easy comparison of events and results at different times throughout the procedure, without losing the ability to visualize and navigate catheters in real-time. The EnSite Velocity System is an open platform, which means that it is compatible with essentially all diagnostic and ablation catheters, recording systems and energy sources used for ablation procedures.
The EnSite Velocity System also continues EnSite’s longstanding ability to reduce fluoroscopy exposure and is the only mapping system capable of supporting both contact and non-contact mapping, giving the EnSite Velocity System unmatched versatility in its ability to map any arrhythmia.
Press release: St. Jude Medical Announces FDA Approval of EnSite Velocity Cardiac Mapping System
Product page: EnSite Velocity Cardiac Mapping System
Flashbacks: SJM Releases New EnSite Cardiac Mapping System; Cardiac Electrophysiology Goes Robotic and 3D with CoHesion; St. Jude Medical Gets FDA OK for Cardiac Image Integration Software
